IL311253A - Antibodies against human monocarboxylate transporter 1 and their uses - Google Patents
Antibodies against human monocarboxylate transporter 1 and their usesInfo
- Publication number
- IL311253A IL311253A IL311253A IL31125324A IL311253A IL 311253 A IL311253 A IL 311253A IL 311253 A IL311253 A IL 311253A IL 31125324 A IL31125324 A IL 31125324A IL 311253 A IL311253 A IL 311253A
- Authority
- IL
- Israel
- Prior art keywords
- seq
- comprises seq
- antibody
- vector
- nucleic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163261177P | 2021-09-14 | 2021-09-14 | |
| US202163272903P | 2021-10-28 | 2021-10-28 | |
| PCT/US2022/076400 WO2023044325A1 (en) | 2021-09-14 | 2022-09-14 | Human monocarboxylate transporter 1 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL311253A true IL311253A (en) | 2024-05-01 |
Family
ID=83558178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL311253A IL311253A (en) | 2021-09-14 | 2022-09-14 | Antibodies against human monocarboxylate transporter 1 and their uses |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11987624B2 (enExample) |
| EP (1) | EP4402172A1 (enExample) |
| JP (2) | JP7753348B2 (enExample) |
| KR (1) | KR20240053656A (enExample) |
| AU (1) | AU2022347031B2 (enExample) |
| CA (1) | CA3230072A1 (enExample) |
| CL (1) | CL2024000733A1 (enExample) |
| CO (1) | CO2024003042A2 (enExample) |
| CR (1) | CR20240133A (enExample) |
| DO (1) | DOP2024000049A (enExample) |
| EC (1) | ECSP24020235A (enExample) |
| IL (1) | IL311253A (enExample) |
| JO (1) | JOP20240054A1 (enExample) |
| MX (1) | MX2024003115A (enExample) |
| TW (1) | TWI842088B (enExample) |
| WO (1) | WO2023044325A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3087259A1 (en) | 2018-01-05 | 2019-07-11 | Immunext, Inc. | Anti-mct1 antibodies and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040132813A1 (en) | 2001-05-30 | 2004-07-08 | Brooks George A. | Glycerol-lactate esters for use as an energy supplement during exercise and recovery |
| WO2012178173A1 (en) | 2011-06-24 | 2012-12-27 | Centrose, Llc | Extracellular targeted drug conjugates |
| GB201418626D0 (en) | 2014-10-20 | 2014-12-03 | Univ London Queen Mary | Method |
| CA3087259A1 (en) * | 2018-01-05 | 2019-07-11 | Immunext, Inc. | Anti-mct1 antibodies and uses thereof |
-
2022
- 2022-09-13 TW TW111134587A patent/TWI842088B/zh active
- 2022-09-14 KR KR1020247011816A patent/KR20240053656A/ko active Pending
- 2022-09-14 US US17/932,039 patent/US11987624B2/en active Active
- 2022-09-14 AU AU2022347031A patent/AU2022347031B2/en active Active
- 2022-09-14 IL IL311253A patent/IL311253A/en unknown
- 2022-09-14 WO PCT/US2022/076400 patent/WO2023044325A1/en not_active Ceased
- 2022-09-14 CA CA3230072A patent/CA3230072A1/en active Pending
- 2022-09-14 JP JP2023515671A patent/JP7753348B2/ja active Active
- 2022-09-14 CR CR20240133A patent/CR20240133A/es unknown
- 2022-09-14 MX MX2024003115A patent/MX2024003115A/es unknown
- 2022-09-14 EP EP22783672.3A patent/EP4402172A1/en active Pending
-
2024
- 2024-03-12 CL CL2024000733A patent/CL2024000733A1/es unknown
- 2024-03-12 DO DO2024000049A patent/DOP2024000049A/es unknown
- 2024-03-13 JO JOJO/P/2024/0054A patent/JOP20240054A1/ar unknown
- 2024-03-13 CO CONC2024/0003042A patent/CO2024003042A2/es unknown
- 2024-03-14 EC ECSENADI202420235A patent/ECSP24020235A/es unknown
-
2025
- 2025-10-01 JP JP2025165282A patent/JP2026004435A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TWI842088B (zh) | 2024-05-11 |
| KR20240053656A (ko) | 2024-04-24 |
| WO2023044325A1 (en) | 2023-03-23 |
| CR20240133A (es) | 2024-05-06 |
| MX2024003115A (es) | 2024-06-19 |
| CL2024000733A1 (es) | 2024-08-30 |
| JP7753348B2 (ja) | 2025-10-14 |
| AU2022347031B2 (en) | 2026-07-23 |
| TW202330602A (zh) | 2023-08-01 |
| CA3230072A1 (en) | 2023-03-23 |
| DOP2024000049A (es) | 2024-06-16 |
| JP2026004435A (ja) | 2026-01-14 |
| WO2023044325A9 (en) | 2024-04-25 |
| ECSP24020235A (es) | 2024-06-28 |
| CO2024003042A2 (es) | 2024-03-18 |
| JOP20240054A1 (ar) | 2024-03-13 |
| JP2023542639A (ja) | 2023-10-11 |
| US20230111363A1 (en) | 2023-04-13 |
| AU2022347031A1 (en) | 2024-03-14 |
| US11987624B2 (en) | 2024-05-21 |
| EP4402172A1 (en) | 2024-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024109678A5 (enExample) | ||
| JP2024522360A5 (enExample) | ||
| CN112135626A (zh) | 抗tigit抗体及其用途 | |
| US20200347130A1 (en) | CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof | |
| JP2021532058A5 (enExample) | ||
| JP2020535799A5 (enExample) | ||
| US20130267688A1 (en) | Novel antibody structures derived from human germline sequences | |
| IL273196B1 (en) | Claudin 6 antibodies and methods of cancer treatment | |
| JP2011527899A5 (enExample) | ||
| RU2009138922A (ru) | Новые анти-r7v-антитела и их применения | |
| WO2007054816A2 (en) | Antibody ultrahumanization by predicted mature cdr blasting and cohort library generation and screening | |
| JP7851923B2 (ja) | インターロイキン1アルファに特異的な真のヒト抗体 | |
| JP7830445B2 (ja) | インターロイキン1アルファに特異的な真のヒト抗体 | |
| FI4200018T3 (fi) | Anti-par-2-vasta-aineet ja niiden käyttömenetelmät | |
| JP2024546763A5 (enExample) | ||
| TW202200620A (zh) | 抗flt3抗體及組合物 | |
| JPWO2020004490A5 (enExample) | ||
| JP2023545005A (ja) | インターロイキン1アルファに特異的な真のヒト抗体 | |
| JP2023545007A (ja) | インターロイキン1アルファに特異的な真のヒト抗体 | |
| CN121152800A (zh) | 特异性结合Claudin18.2的抗体及其制法和应用 | |
| US20120316085A1 (en) | Antibody humanization by framework assembly | |
| JP2026004435A5 (enExample) | ||
| CN117143238A (zh) | 抗人cd24抗体及其应用 | |
| CN110372793B (zh) | Pd-l1的纳米抗体及其临床应用 | |
| JP2023503228A (ja) | ヒト4-1bbに結合可能な分子及びその応用 |